– USA, CA – Amunix Pharmaceuticals, Inc., a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the appointment of Trisha Millican to its Board of Directors.
The company also announced the appointment of Zeeshan Merchant as CFO, joining with over 15 years of experience in biotechnology as an investment banker and investor. He joins from Morgan Stanley, where he served as an Executive Director in the healthcare investment banking group, advising biotechnology companies on financings and strategic matters.
Ms. Millican, who will head the audit committee, brings over 20 years of experience in the life science industry, including experience with debt and equity financings, mergers and acquisitions, licensing transactions, co-development, and promotional arrangements, and commercial product launches.
“We are excited to welcome Zeeshan and Trisha, both leaders in the financial services and healthcare industry, to Amunix,” said CEO, Angie You. “Their expertise and leadership will be invaluable as we continue to grow Amunix and transition into a clinical stage company. We are excited about the potential of our lead development candidate, AMX-818, a protease-activated T cell engager prodrug targeting HER2+ solid tumors, to significantly benefit patients.”
About Trisha Millican
Trisha Millican has 20 years of leadership experience in the life science industry encompassing debt and equity financings, mergers and acquisitions, licensing transactions, co-development and promotional arrangements, and commercial product launches. She is currently the CFO of Metacrine. Before Metacrine, Ms. Millican was the SVP, Finance at Seragon, a private biotechnology company focused on developing Selective Estrogen Receptor Degraders targeting hormone-dependent cancers, which was acquired by Genentech. Before Seragon, she served as VP, Finance at Aragon, a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, which was acquired by Johnson and Johnson. Before Aragon, Ms. Millican worked in various senior financial management roles at Zogenix, a pharmaceutical company developing and commercializing innovative central nervous system therapies for people living with serious and life-threatening rare central nervous system disorders and medical conditions. Ms. Millican spent five years with the public accounting firm Deloitte LLP.
She holds a B.S. in Accountancy from the University of San Diego and is a certified public accountant in the state of California.
About Zeeshan Merchant
Zeeshan Merchant has over 15 years of experience in biotechnology as an investment banker and investor. Before joining Amunix, Mr. Merchant worked as an investment banker at Morgan Stanley, serving as an Executive Director in the firm’s healthcare investment banking group. In this role, Mr. Merchant advised U.S. and Asia based biotechnology companies on financings and strategic matters, and successfully executed over 50 transactions, including $20 billion in financing and $25 billion in mergers and acquisitions. Before Morgan Stanley, Mr. Merchant worked as Senior Analyst at Ayer Capital, a healthcare dedicated investment fund. In this role, Mr. Merchant identified and analyzed biotechnology and healthcare investments globally. Before Ayer Capital, Mr. Merchant worked as a private equity Associate at TA Associates, a leading, global growth private equity firm.
Mr. Merchant received a B.A. in Economics from the University of Pennsylvania.
About Amunix Pharmaceuticals
Amunix Pharmaceuticals, based in South San Francisco, CA, is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. The company is leveraging its proprietary T cell engager and cytokine platforms to advance a pipeline of novel masked prodrugs that are preferentially activated in the tumor microenvironment. Both platforms utilize Amunix’s proprietary masking technology that has been clinically validated to extend drug half-life with limited immunogenicity. Amunix is advancing its lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic, and has several earlier programs underway. Amunix is also working on their first protease-activated masked cytokine program, IL12-XPAC, which is in discovery.
For more information: https://www.amunix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
